Besponsa

Chemical Nameinotuzumab ozogamicin
Dosage FormInjection (intravenous; 0.9 mg/vial)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyPfizer
Approval Year2017

Indication

  • Indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Last updated on 4/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pediatric acute lymphoblastic leukemia, version 2.2020. 2020Journal of the National Comprehensive Cancer Network
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. 2020Journal for ImmunoTherapy of Cancer
NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. 2017Journal of the National Comprehensive Cancer Network